Zhengye Biotechnology Holding (ZYBT) Non-Current Debt (2023 - 2025)

Zhengye Biotechnology Holding (ZYBT) has reported Non-Current Debt for 3 consecutive years, with $1.2 million the latest figure, recorded in Q4 2025.

• Quarterly Non-Current Debt rose 86.73% year-over-year to $1.2 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $1.2 million (up 86.73% YoY) and the FY2025 annual result came in at $1.3 million, up 92.4% from the prior year.
• Non-Current Debt rose to $1.2 million in Q4 2025 per ZYBT's latest filing, from $656000.0 in the prior quarter.
• Over the last five years, Non-Current Debt for ZYBT reached as high as $1.4 million in Q4 2023 and fell as low as $656000.0 in Q2 2025.
• A 3-year average of $989876.3 and a median of $958010.0 in 2024 frame the typical range for Non-Current Debt.
• Annual changes were most pronounced in 2024 — Non-Current Debt tumbled 51.84% — and 2025, when it surged 86.73%.
• Year by year, Non-Current Debt stood at $1.4 million in 2023, then slumped by 51.84% to $668235.5 in 2024, then jumped by 86.73% to $1.2 million in 2025.
• According to Business Quant data, Non-Current Debt over the past three periods registered $1.2 million, $656000.0, and $668235.5 for Q4 2025, Q2 2025, and Q4 2024 respectively.